WO2007008541A3 - Cellular cholesterol absorption modifiers - Google Patents

Cellular cholesterol absorption modifiers Download PDF

Info

Publication number
WO2007008541A3
WO2007008541A3 PCT/US2006/026242 US2006026242W WO2007008541A3 WO 2007008541 A3 WO2007008541 A3 WO 2007008541A3 US 2006026242 W US2006026242 W US 2006026242W WO 2007008541 A3 WO2007008541 A3 WO 2007008541A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol absorption
cellular cholesterol
absorption modifiers
modifiers
cellular
Prior art date
Application number
PCT/US2006/026242
Other languages
French (fr)
Other versions
WO2007008541A2 (en
Inventor
Elisabeth M Gardiner
Sergio G Duron
Mark E Massari
Daniel L Severance
Joseph E Semple
Original Assignee
Kalypsys Inc
Elisabeth M Gardiner
Sergio G Duron
Mark E Massari
Daniel L Severance
Joseph E Semple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc, Elisabeth M Gardiner, Sergio G Duron, Mark E Massari, Daniel L Severance, Joseph E Semple filed Critical Kalypsys Inc
Publication of WO2007008541A2 publication Critical patent/WO2007008541A2/en
Publication of WO2007008541A3 publication Critical patent/WO2007008541A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.
PCT/US2006/026242 2005-07-08 2006-07-05 Cellular cholesterol absorption modifiers WO2007008541A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US69765905P 2005-07-08 2005-07-08
US69768605P 2005-07-08 2005-07-08
US69781405P 2005-07-08 2005-07-08
US60/697,659 2005-07-08
US60/697,814 2005-07-08
US60/697,686 2005-07-08
US72764605P 2005-10-17 2005-10-17
US60/727,646 2005-10-17
US78230306P 2006-03-13 2006-03-13
US60/782,303 2006-03-13

Publications (2)

Publication Number Publication Date
WO2007008541A2 WO2007008541A2 (en) 2007-01-18
WO2007008541A3 true WO2007008541A3 (en) 2007-07-26

Family

ID=37637726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026242 WO2007008541A2 (en) 2005-07-08 2006-07-05 Cellular cholesterol absorption modifiers

Country Status (1)

Country Link
WO (1) WO2007008541A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
RU2490015C2 (en) * 2008-02-22 2013-08-20 Райджел Фармасьютикалз, Инк. Use of 2,4-diaminopyrimidines for treating atherosclerosis
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7061394B2 (en) 2017-03-31 2022-04-28 国立大学法人 長崎大学 Quinoline compounds and anti-RNA virus drugs
JP7357934B2 (en) 2018-04-12 2023-10-10 パーデュー・リサーチ・ファウンデーション benzamide antibacterial agent

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
AR057072A1 (en) 2005-06-22 2007-11-14 Astrazeneca Ab CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
HUE028987T2 (en) * 2005-11-01 2017-01-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
TW200804347A (en) 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
US7514566B2 (en) 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
WO2008003753A1 (en) * 2006-07-07 2008-01-10 Biovitrum Ab (Publ) Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity
US8759342B2 (en) 2006-07-31 2014-06-24 Janssen Pharmaceutica Nv Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists
WO2008127274A2 (en) * 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
MX2009003821A (en) 2006-10-10 2009-05-25 Amgen Inc N-aryl pyrazole compounds for use against diabetes.
DE102006050515A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
WO2008055945A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
PE20080932A1 (en) * 2006-11-10 2008-07-13 Wyeth Corp N-SUBSTITUTED PIPERIDINYL 4-ARYLSULFONAMIDES AS MODULATORS OF FRIZZLED-RELATED SECRETED PROTEIN 1 (SFRP-1)
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
EP2000140A1 (en) * 2007-06-05 2008-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
US8124632B2 (en) * 2007-08-03 2012-02-28 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
WO2009037247A1 (en) * 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
US8389736B2 (en) 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
JP2011515341A (en) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド Conformationally restricted carboxylic acid derivatives useful for the treatment of metabolic disorders
CA2731224A1 (en) 2008-07-23 2010-01-28 Sanjay A. Desai Inhibitors of the plasmodial surface anion channel as antimalarials
ES2379762T3 (en) 2008-08-02 2012-05-03 Janssen Pharmaceutica N.V. Urotensin II receptor antagonists
AU2009279616A1 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
EP2321267A2 (en) * 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Monoaryl aminotetralines
WO2010030757A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8383094B2 (en) * 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
MX2011006094A (en) 2008-12-08 2011-11-29 Gilead Connecticut Inc Imidazopyrazine syk inhibitors.
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN102405043B (en) 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 Preceding neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
TW201035088A (en) * 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP3626240A1 (en) * 2009-03-02 2020-03-25 StemSynergy Therapeutics, Inc. Process of preparation of a n-aryl benzyl sulfonamide substituted with an amido group
AU2010241742A1 (en) * 2009-04-27 2011-11-17 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
EP2429986B1 (en) 2009-05-12 2016-11-16 Romark Laboratories, L.C. Haloalkyl heteroaryl benzamide compounds
WO2010138828A2 (en) * 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
CN108042535A (en) 2009-06-26 2018-05-18 罗马克实验室有限公司 For treating the Compounds and methods for of influenza
JP2012532850A (en) * 2009-07-10 2012-12-20 ビバリス Substituted pyrrolidinones as inhibitors of hepatitis C NS5B polymerase, pharmaceutical compositions thereof, and their therapeutic use
US8673913B2 (en) * 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
JP5938352B2 (en) 2010-03-11 2016-06-22 ギリアード コネチカット， インコーポレイテッド Imidazopyridine SYK inhibitor
RU2576036C2 (en) * 2010-03-17 2016-02-27 Тайвекс Терапьютикс Корпорейшн Modulators of hec1 activity and methods therefor
MX2012012531A (en) * 2010-04-27 2013-04-03 Astellas Pharma Inc IMIDAZO[1,2-a]PYRIDINE DERIVATIVE.
KR20110123657A (en) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
CN101899051B (en) * 2010-05-17 2013-03-20 中国人民解放军第二军医大学 1-azaxanthone-3-formamide compounds as well as preparation method and antitumor application thereof
US20120149715A1 (en) * 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
CN103415289B (en) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 Pro-neurogenic compounds
CN103168032A (en) 2010-08-05 2013-06-19 安美基公司 Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
EP2886120B1 (en) 2010-10-29 2019-06-19 Emory University Quinazoline derivatives, compositions and uses related thereto
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
DE102010044131A1 (en) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
DK3366688T3 (en) 2010-12-08 2022-05-02 Us Health Substituted pyrazole pyrimidines as glucocerebrosidase activators
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
WO2012097196A1 (en) * 2011-01-12 2012-07-19 Acea Biosciences Inc. Pyrazolopyrimidine derivatives and uses as anticancer agents
CN102670625B (en) * 2011-03-18 2014-05-28 中国人民解放军第二军医大学 Application of urea compound
CN103608017B (en) 2011-04-12 2017-02-15 美国卫生和人力服务部 Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
KR101369584B1 (en) * 2011-04-19 2014-03-06 일양약품주식회사 Phenyl-isoxazol derivatives and preparation process thereof
US20120302573A1 (en) * 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
CN103649074B (en) * 2011-07-07 2016-05-11 默克专利股份公司 Be used for the treatment of the azacyclo-of the replacement of cancer
ES2899000T3 (en) 2011-07-18 2022-03-09 Merck Patent Gmbh Benzamides
KR20140063605A (en) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 Heterocyclic compounds and uses thereof
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (en) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Modulators of hec1 activity and methods therefor
CN103254151B (en) * 2012-02-20 2015-10-28 北京大学 Benzo isothiazole 5-LOX and mPGES-1 inhibitor and application
WO2013148333A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
KR20150008468A (en) * 2012-05-09 2015-01-22 폰다지오네 이탈리아나 스클레로시 멀티플라 - 에프아이에스엠 온러스 GPR17 receptor modulators
ITMI20120786A1 (en) * 2012-05-09 2013-11-10 Fond Italiana Sclerosi M Ultipla Fism Onlu MODULATORS OF THE GPR17 RECEPTOR
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP6238460B2 (en) 2012-09-27 2017-11-29 興和株式会社 Dyslipidemia therapeutic agent
KR101488583B1 (en) * 2013-02-06 2015-02-03 부산대학교 산학협력단 New compounds having skin whitening activity and medical use thereof
WO2014172453A2 (en) * 2013-04-16 2014-10-23 Philadelphia Health And Education Corporation D/B/A Drexel University College Of Medicine Novel compositions useful in treating brain-related diseases or disorders and methods using same
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
WO2015046193A1 (en) * 2013-09-25 2015-04-02 塩野義製薬株式会社 Aromatic heterocyclic amine derivative having trpv4 inhibiting activity
EP3052480B1 (en) * 2013-09-30 2020-11-11 The Texas A & M University System Compositions associated with and methods of managing neutrophil movement
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
CN103709096B (en) * 2013-12-24 2017-01-18 中国人民解放军第二军医大学 Urea type derivative used as nicotinamide ribose phosphate transferase inhibitor, as well as preparation method and application thereof
DK3119397T3 (en) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders
WO2016022460A1 (en) 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (en) 2015-07-06 2022-04-28 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
MA43677A (en) 2016-02-25 2018-11-28 Asceneuron Sa GLYCOSIDASE INHIBITORS
CN109071526B (en) 2016-02-25 2023-02-28 阿森纽荣股份公司 Acid addition salts of piperazine derivatives
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
WO2018033918A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
PL3570834T3 (en) 2017-01-11 2022-05-23 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
WO2018217757A1 (en) * 2017-05-22 2018-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers
RS63343B1 (en) 2017-08-07 2022-07-29 Alkermes Inc Bicyclic inhibitors of histone deacetylase
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
WO2020097408A1 (en) * 2018-11-09 2020-05-14 Nimbus Artemis, Inc. Acly inhibitors and uses thereof
CN109574920B (en) * 2018-12-25 2022-03-04 药大制药有限公司 3-nitrile-6-cyclopropyl pyridine IDO1 inhibitor and application thereof
CN109627205B (en) * 2019-01-11 2022-04-12 贵州大学 Preparation method and application of carbazolyl isopropanolamine derivatives
CN109627206B (en) * 2019-01-11 2022-04-12 贵州大学 Preparation method and application of carbazolyl isopropanolamine derivatives with chiral centers
EP4211131A1 (en) * 2020-09-11 2023-07-19 The Regents of the University of California Compositions and methods for treating muscular dystrophies
WO2022159445A1 (en) * 2021-01-19 2022-07-28 Metrea Biosciences, Inc. Compounds and methods of activating lipoprotein lipase
GB202206054D0 (en) * 2022-04-26 2022-06-08 Cerevance Ltd Novel Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223593A2 (en) * 1985-11-19 1987-05-27 Glaxo Group Limited Phenoxyalkylcarboxylic acids and esters and their preparation and pharmaceutical formulation
EP0472449A2 (en) * 1990-07-31 1992-02-26 Lipha, Lyonnaise Industrielle Pharmaceutique Substituted sulfonamides, processes for their preparation and medicines containing them
WO2003043985A1 (en) * 2001-11-21 2003-05-30 Novartis Ag Heterocyclic compounds and methods of use
WO2005015988A1 (en) * 2003-07-17 2005-02-24 Schering Corporation Npc1l1 (npc3) and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223593A2 (en) * 1985-11-19 1987-05-27 Glaxo Group Limited Phenoxyalkylcarboxylic acids and esters and their preparation and pharmaceutical formulation
EP0472449A2 (en) * 1990-07-31 1992-02-26 Lipha, Lyonnaise Industrielle Pharmaceutique Substituted sulfonamides, processes for their preparation and medicines containing them
US5476846A (en) * 1990-07-31 1995-12-19 Lipha, Lyonnaise Industrielle Pharmaceutique Substituted sulfonamides, process of preparation and medicines containing same
WO2003043985A1 (en) * 2001-11-21 2003-05-30 Novartis Ag Heterocyclic compounds and methods of use
WO2005015988A1 (en) * 2003-07-17 2005-02-24 Schering Corporation Npc1l1 (npc3) and methods of use thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
RU2490015C2 (en) * 2008-02-22 2013-08-20 Райджел Фармасьютикалз, Инк. Use of 2,4-diaminopyrimidines for treating atherosclerosis
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7061394B2 (en) 2017-03-31 2022-04-28 国立大学法人 長崎大学 Quinoline compounds and anti-RNA virus drugs
JP7357934B2 (en) 2018-04-12 2023-10-10 パーデュー・リサーチ・ファウンデーション benzamide antibacterial agent

Also Published As

Publication number Publication date
WO2007008541A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2007008541A3 (en) Cellular cholesterol absorption modifiers
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2008011557A3 (en) Heteroaryl inhibitors of rho kinase
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
ZA200710609B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ZA200710604B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP1756106A4 (en) Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2010032875A3 (en) Heterocyclic carboxamide compounds
EP1761532A4 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008033562A3 (en) Kinase inhibitor compounds
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2007092622A3 (en) Compositions and methods for treating bone
IL187738A0 (en) New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2007139871A3 (en) Methods and materials for making simvastatin and related compounds
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06786403

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06786403

Country of ref document: EP

Kind code of ref document: A2